R

    Rapport Therapeutics, Inc. Common Stock (RAPP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $48.67
    -0.10 (-0.20%)

    Market Cap: $2.34B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(6/9)
    Avg Surprise
    -10.76%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.23
    Range$-1.36 - $-1.12
    9 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-1.00+18.8%
    60d ago$-1.00+18.8%
    30d ago$-1.01+18.4%
    7d ago$-1.23+0.0%
    Current$-1.23
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Dec 31, 2026
    EPS Consensus$-1.16
    Range$-1.58 - $-0.92
    9 analysts
    Revenue Consensus
    $14M
    Range$14M - $14M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.16---
    Sep 26EST
    		-$-1.23---
    Jun 26
    		$-1.19$-0.93-27.96%Miss-58.7%
    Mar 26
    		$-0.42$-0.71+40.85%Beat+38.2%
    Dec 25
    		$-0.72$-0.67-6.78%Miss-26.3%
    Sep 25
    		$-0.71$-0.73+2.74%Beat-42.0%
    Jun 25
    		$-0.75$-0.87+13.79%Beat+55.9%
    Mar 25
    		$-0.68$-0.74+8.11%Beat+39.3%
    Dec 24
    		$-0.57$-0.70+18.57%Beat-
    Sep 24
    		$-0.50$-0.52+3.85%Beat-
    Jun 24
    		$-1.70$-0.68-150.00%Miss-
    Mar 24
    		$-1.12$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-16.01EV/EBITDAN/A
    Price/FCF-23.78xFCF Yield-4.20%
    Profitability
    Profit Margin0.00%Operating Margin-768.00%
    ROE-40.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio15.72xQuick Ratio15.72x
    Trading Statistics
    Beta0.97Avg Volume285.87K
    52-Week High$52.9352-Week Low$14.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$49.54
    SMA 20$47.93
    SMA 50$43.59
    SMA 200$34.35
    EMA 10$49.24
    EMA 20$47.81
    EMA 50$44.35
    EMA 200$35.19

    MACD

    Line: 2.00Signal: 2.12Hist: -0.13

    ADX

    ADX: 42.3+DI: 27.0-DI: 16.7

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down20.0
    PSAR$52.84

    Bollinger Bands

    Upper Band$52.95
    Lower Band$42.92
    %B Position2093%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    56.3

    Momentum Oscillators

    Stoch %K48.1
    Stoch %D68.4
    Williams %R-64.9
    ROC (10d)0.5%
    Momentum0.25
    CCI (20d)27.8
    MFI (14d)47.4

    Volatility Measures

    ATR (14d)$2.23(4.6%)
    StdDev (20d)2.51
    Hist Vol48.9%(High)

    Volume Flow

    VWAP$48.50
    OBV28.7M
    AD Line-8.3M
    CMF (20d)0.237

    Volume Metrics

    Avg Vol (20d)284.4K
    Vol Ratio0.8x
    VWMA (20d)$47.96

    Pivot Points

    R3$52.48
    R2$51.58
    R1$50.17
    Pivot Point$49.27
    S1$47.87
    S2$46.97
    S3$45.56

    Advanced Oscillators

    TSI26.11
    Ultimate Osc56.8
    KST178.37

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$20.00M$0$0$0$0$720,000$0$0$0$0$0
    Cost of Revenue$0$0$265,000$0$0$0$260,000$0$0$0$76,000$0
    Gross Profit$0$20.00M$-265,000$0$0$0$-260,000$0$0$0$-76,000$0
    Operating Expenses$60.81M$44.22M$38.51M$29.99M$29.50M$27.11M$23.52M$21.64M$20.80M$17.09M$14.72M$9.56M
    R&D$51.41M$32.72M$30.26M$22.28M$22.68M$19.57M$17.20M$15.54M$15.69M$12.50M$11.80M$7.58M
    SG&A$9.39M$11.50M$8.25M$7.71M$6.82M$7.54M$6.32M$6.10M$5.11M$4.59M$3.00M$1.98M
    Operating Income$-60,806,000$-24,215,000$-38,509,000$-29,986,000$-29,496,000$-27,108,000$-23,521,000$-21,640,000$-20,800,000$-17,094,000$-14,794,000$-9,564,000
    Interest Income$4.19M$4.36M$4.75M$3.06M$2.76M$3.04M$3.54M$4.10M$2.68M$1.81M$1.38M$856,000
    Interest Expense$0$0$0$0$0$0$0$0$0$5.58M$0$0
    Income Before Tax$-56,615,000$-19,857,000$-33,763,000$-26,925,000$-26,732,000$-24,063,000$-19,980,000$-17,537,000$-18,121,000$-22,669,000$-13,513,000$-8,708,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$6,000$1,000
    Net Income$-56,615,000$-19,857,000$-33,763,000$-26,925,000$-26,732,000$-24,063,000$-19,980,000$-17,537,000$-18,121,000$-22,669,000$-13,519,000$-8,709,000
    EBITDA$-59,654,000$-23,770,000$-39,316,000$-29,526,000$-28,853,000$-26,889,000$-22,701,000$-23,385,000$-21,421,000$-25,310,000$-13,338,000$-9,541,000
    EBIT$-60,806,000$-24,215,000$-38,509,000$-29,986,000$-29,496,000$-27,108,000$-23,521,000$-21,640,000$-20,800,000$-24,484,000$-13,391,000$-9,564,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RAPP

    News

    Rapport (NASDAQ: RAPP) insider lines up stock sale after August plan trades

    Rapport Therapeutics, Inc. officer Krishnaswamy Yeleswaram has filed a Rule 144 notice to sell 37,000 shares of common stock, valued at $1,825,210.00, through Morgan Stanley Smith Barney LLC. These shares were acquired from the vesting of founders shares between June 2024 and February 2025. This planned sale follows previous 10b5-1 plan sales by the same insider in August 2026.

    Stock Titan•8/25/26•
    Neutral

    Rapport Therapeutics (RAPP) officer flags $553K stock sale plan

    An officer at Rapport Therapeutics (RAPP), Krishnaswamy Yeleswaram, plans to sell 11,472 shares of common stock, valued at approximately $553,409.28, under Rule 144. These shares were acquired from the vesting of founders shares between June and August 2024. The filing also notes a previous 10b5-1 sale of 404 shares for $20,159.60 in the past three months.

    Stock Titan•8/24/26•
    Neutral

    Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

    Rapport Therapeutics will host a virtual Key Opinion Leader (KOL) event on September 22, 2026, to discuss the challenges in treating bipolar mania and the potential of their investigational drug, RAP-219. The event will feature leading experts, including Mauricio Tohen and Gary Sachs, who will present the underlying biology and clinical program for RAP-219, with topline Phase 2 data expected in October 2026. RAP-219 is a potential first-in-class precision medicine targeting specific AMPA receptors, showing promise for bipolar mania, focal onset seizures, and primary generalized tonic-clonic seizures.

    GlobeNewswire•8/24/26•
    Somewhat-Bullish

    Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

    Rapport Therapeutics will host a virtual KOL event on September 22, 2026, to discuss the unmet needs in bipolar mania and their investigational drug, RAP-219. The event will feature leading experts who will delve into the challenges of current treatments, the scientific rationale behind RAP-219, and an overview of its ongoing Phase 2 trial, with topline data expected in October 2026. RAP-219 is a potential first-in-class treatment targeting TARPγ8-specific AMPA receptors, aiming for a differentiated safety and efficacy profile.

    WBOC TV•8/24/26•
    Somewhat-Bullish

    BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $65

    BTIG has reiterated its Buy rating for Rapport Therapeutics (RAPP.US) and maintained its target price at $65. This indicates a continued positive outlook from the investment firm regarding the company's stock performance.

    Moomoo•8/21/26•
    Bullish

    Frequently Asked Questions About RAPP

    Does RAPP pay dividends?
    Rapport Therapeutics, Inc. Common Stock (RAPP) does not currently pay a regular dividend.
    What is RAPP's market cap?
    Rapport Therapeutics, Inc. Common Stock (RAPP) has a market capitalization of $2.34B with a current stock price of $48.67.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In